Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo Ltd ADR (OP:DSNKY)

24.28 +1.01 (+4.34%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 604,322
Open 23.86
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 23.27
Today's Range 23.83 - 24.61
52wk Range 20.92 - 42.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results. 
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga

Performance

YTD
-11.1%
-11.1%
1 Month
+10.6%
+10.6%
3 Month
+1.6%
+1.6%
6 Month
-17.9%
-17.9%
1 Year
-30.6%
-30.6%

More News

Read More
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
Via Benzinga
Exposures Product Safety
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
Via Benzinga
Exposures Product Safety
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024
Via InvestorPlace
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Via Benzinga
Exposures Product Safety
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
Via Benzinga
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Via Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
Via Benzinga
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Via MarketBeat
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
Via Benzinga
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Via Benzinga
Exposures Product Safety
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Via InvestorPlace
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Via Benzinga
Exposures Product Safety
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Via Benzinga
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
Via InvestorPlace
Double Good News For AstraZeneca's Breast Cancer Drugs
Via Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Via Benzinga
Exposures Product Safety
What's Going On With Pfizer Stock Today?
Via Benzinga
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
Via Benzinga
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Via Benzinga
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
Via The Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Via Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
Via Benzinga

Frequently Asked Questions

Is Daiichi Sankyo Ltd ADR publicly traded?
Yes, Daiichi Sankyo Ltd ADR is publicly traded.
What exchange does Daiichi Sankyo Ltd ADR trade on?
Daiichi Sankyo Ltd ADR trades on the OTC Traded
What is the ticker symbol for Daiichi Sankyo Ltd ADR?
The ticker symbol for Daiichi Sankyo Ltd ADR is DSNKY on the OTC Traded
What is the current price of Daiichi Sankyo Ltd ADR?
The current price of Daiichi Sankyo Ltd ADR is 24.28
When was Daiichi Sankyo Ltd ADR last traded?
The last trade of Daiichi Sankyo Ltd ADR was at 05/16/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.